BR112018071586A2 - uso de beta-agonistas da tireoide - Google Patents

uso de beta-agonistas da tireoide

Info

Publication number
BR112018071586A2
BR112018071586A2 BR112018071586-7A BR112018071586A BR112018071586A2 BR 112018071586 A2 BR112018071586 A2 BR 112018071586A2 BR 112018071586 A BR112018071586 A BR 112018071586A BR 112018071586 A2 BR112018071586 A2 BR 112018071586A2
Authority
BR
Brazil
Prior art keywords
agonists
thyroid beta
thyroid
beta
adrenoleukodystrophy
Prior art date
Application number
BR112018071586-7A
Other languages
English (en)
Inventor
Jiang Hongjian
Lian Brian
Hanley Rochelle
Dinerman Misha
Erion Mark
Boyer Serge
Original Assignee
Viking Therapeutics, Inc.
Metabasis Therapeutics, Inc.
Jiang Hongjian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics, Inc., Metabasis Therapeutics, Inc., Jiang Hongjian filed Critical Viking Therapeutics, Inc.
Publication of BR112018071586A2 publication Critical patent/BR112018071586A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

são apresentados métodos úteis para o tratamento de adrenoleucodistrofia relacionada com x.
BR112018071586-7A 2016-04-22 2017-04-24 uso de beta-agonistas da tireoide BR112018071586A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (1)

Publication Number Publication Date
BR112018071586A2 true BR112018071586A2 (pt) 2019-02-12

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071586-7A BR112018071586A2 (pt) 2016-04-22 2017-04-24 uso de beta-agonistas da tireoide

Country Status (9)

Country Link
US (2) US11351183B2 (pt)
EP (1) EP3445373B1 (pt)
JP (1) JP6931042B2 (pt)
KR (1) KR102407059B1 (pt)
AU (1) AU2017252126B2 (pt)
BR (1) BR112018071586A2 (pt)
CA (1) CA3021681A1 (pt)
MX (1) MX2018012900A (pt)
WO (1) WO2017185087A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185087A1 (en) 2016-04-22 2017-10-26 Viking Therapeutics Use of thyroid beta-agonists
US11787828B2 (en) * 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
JP2007524656A (ja) 2003-10-23 2007-08-30 セルジーン・コーポレーション 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
EP2289500A1 (en) 2004-12-08 2011-03-02 ReVision Therapeutics, Inc. Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
KR102540778B1 (ko) 2011-06-21 2023-06-07 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
CA2976922A1 (en) 2015-02-20 2016-08-25 Oregon Health & Science University Derivatives of sobetirome
BR112018015561B1 (pt) 2016-02-29 2023-03-28 Philip Morris Products S.A. Recipiente com tampa articulada e molde
AU2017252122B2 (en) 2016-04-22 2023-02-09 Viking Therapeutics, Inc. Use of Thyroid beta-Agonists
WO2017185087A1 (en) 2016-04-22 2017-10-26 Viking Therapeutics Use of thyroid beta-agonists
KR102331596B1 (ko) 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체

Also Published As

Publication number Publication date
MX2018012900A (es) 2019-07-01
KR20190039027A (ko) 2019-04-10
US20190321379A1 (en) 2019-10-24
AU2017252126B2 (en) 2023-02-09
US20220257618A1 (en) 2022-08-18
EP3445373A1 (en) 2019-02-27
WO2017185087A1 (en) 2017-10-26
AU2017252126A1 (en) 2018-11-08
JP2019515033A (ja) 2019-06-06
US11951114B2 (en) 2024-04-09
EP3445373A4 (en) 2019-12-18
JP6931042B2 (ja) 2021-09-01
EP3445373B1 (en) 2024-08-21
CA3021681A1 (en) 2017-10-26
US11351183B2 (en) 2022-06-07
KR102407059B1 (ko) 2022-06-10

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018071586A2 (pt) uso de beta-agonistas da tireoide
BR112018071559A2 (pt) uso de beta-agonistas da tireoide
BR112017027721A2 (pt) formulação de alta concentração
CL2018003283S1 (es) Automóvil (divisional solicitud 201800156).
UA114708U (uk) Тяговий привід електробуса
EA201890727A1 (ru) Модуляторы взаимодействия сестрина-gator2 и их применение
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos
UA101750U (ru) Применение омега как органопротектора при токсическом гепатите

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]